North Carolina 2025 2025-2026 Regular Session

North Carolina House Bill H525 Introduced / Bill

Filed 03/26/2025

                    GENERAL ASSEMBLY OF NORTH CAROLINA 
SESSION 2025 
H 	D 
HOUSE BILL DRH10161-MGa-124  
 
 
 
Short Title: Reorganize & Fund Rare Disease Adv. Council. 	(Public) 
Sponsors: Representative Carney. 
Referred to:  
 
*DRH10161 -MGa-124* 
A BILL TO BE ENTITLED 1 
AN ACT REVISING THE COMPOSITION AND DUTIES OF THE ADVISORY COUNCIL 2 
ON RARE DISEASES; TRANSFERRING THE COUNCIL TO THE DEPARTMENT OF 3 
HEALTH AND HUMAN SERVICES; AND APPROPRIATING FUNDS TO THE 4 
DEPARTMENT OF HEALTH AND HUMAN SERVICES TO COVER THE OPERATING 5 
EXPENSES OF THE COUNCIL. 6 
The General Assembly of North Carolina enacts: 7 
SECTION 1. Part 6 of Article 1B of Chapter 130A of the General Statutes reads as 8 
rewritten: 9 
"Part 6. Taylor's Law Establishing the Advisory Council on Rare Diseases. 10 
"§ 130A-33.65.  Advisory Council on Rare Diseases; membership; terms; compensation; 11 
meetings; quorum. 12 
(a) Short Title. – This Part shall be known as Taylor's Law Establishing the Advisory 13 
Council on Rare Diseases. 14 
(a1) Establishment of Advisory Council. – There is established the Advisory Council on 15 
Rare Diseases within the School of Medicine of the University of North Carolina at Chapel Hill 16 
Department of Health and Human Services to advise the Governor, the Secretary, and the General 17 
Assembly on research, diagnosis, treatment, and education relating to rare diseases. This Part 18 
shall be known as Taylor's Law Establishing the Advisory Council on Rare Diseases. For 19 
purposes of this Part, "rare disease" has the same meaning as provided in 21 U.S.C. § 360bb. 20 
(b) Advisory Council Membership. – The advisory council shall consist of 19 members 21 
to be appointed as follows: 22 
(1) Upon the recommendation of the Dean of the School of Medicine of the 23 
University of North Carolina at Chapel Hill, the The Secretary shall appoint 24 
members to the advisory council as follows:the following 15 members: 25 
a. A physician Two physicians licensed and practicing in this State with 26 
experience researching, diagnosing, or treating rare diseases. 27 
b. A medical researcher with experience conducting research concerning 28 
rare diseases. 29 
c. A One registered nurse or advanced practice registered nurse licensed 30 
and practicing in the State with experience treating rare diseases. 31 
d. One rare diseases survivor. 32 
e. One member who represents a rare diseases foundation. 33 
f. One representative researcher from each an academic research 34 
institution in this State that receives any grant funding for rare diseases 35 
research. 36 
H.B. 525
Mar 26, 2025
HOUSE PRINCIPAL CLERK General Assembly Of North Carolina 	Session 2025 
Page 2  	DRH10161-MGa-124 
g. One parent of a childhood rare disease survivor. 1 
h. One hospital administrator, or the hospital administrator's designee, 2 
representing a hospital in the State that provides care to persons 3 
diagnosed with a rare disease. 4 
i. Two persons age 18 or older who have been diagnosed with a rare 5 
disease. 6 
j. Two persons age 18 or older who are, or were previously, caregivers 7 
to a person diagnosed with a rare disease. 8 
k. One representative of a rare disease patient organization that operates 9 
in the State. 10 
l. One pharmacist licensed and practicing in this State with knowledge 11 
and experience regarding drugs used to treat rare diseases. 12 
m. One representative of the life sciences, biotechnology, or 13 
biopharmaceutical industry that either focuses on research efforts 14 
related to the development of therapeutic products for persons 15 
diagnosed with a rare disease or has demonstratable understanding of 16 
the path to commercialization of such products. 17 
n. Two representatives of a health benefit plan or health insurer, at least 18 
one of whom is a representative of a North Carolina Medicaid 19 
Managed Care health plan. 20 
o. One genetic counselor with experience providing services to persons 21 
diagnosed with a rare disease or caregivers of persons diagnosed with 22 
a rare disease. 23 
(2) The chairs of the Joint Legislative Oversight Committee on Health and Human 24 
Services, or the chairs' designees, shall serve on the advisory council. A 25 
member of the advisory council who is designated by the chairs of the Joint 26 
Legislative Oversight Committee on Health and Human Services may be a 27 
member of the General Assembly. 28 
(2a) One member appointed by the President Pro Tempore of the Senate. 29 
(2b) One member appointed by the Speaker of the House of Representatives. 30 
(2c) One member appointed by the Governor. 31 
(3) The Secretary, or the Secretary's designee, shall serve as an ex officio, 32 
nonvoting member of the advisory council. 33 
(c) Members Length of Terms. – All initial members appointed pursuant to subsection 34 
(b) of this section to the advisory council shall serve for a term of three years, and no member 35 
initial member, except for the initial physician members and the initial member representing a 36 
rare disease patient organization, shall serve more than three consecutive terms. The initial 37 
physician members and the initial member representing a rare disease patient organization may 38 
serve for up to four consecutive terms. Thereafter, members appointed by the President Pro 39 
Tempore of the Senate, the Speaker of the House of Representatives, and the Governor shall 40 
serve for a term of two years; and members appointed by the Secretary shall serve for a term of 41 
two, three, or four years, as determined by the chair of the advisory council. 42 
(c1) Vacancies and Removals. – Any appointment to fill a vacancy on the advisory council 43 
created by the resignation, dismissal, death, or disability of a member shall be filled by the 44 
appointing authority for the balance of the unexpired term. Each appointing authority may 45 
remove any member appointed by that appointing authority for misfeasance, malfeasance, or 46 
nonfeasance. 47 
(d) Per Diem and Expenses. – Members of the advisory council shall receive per diem 48 
and necessary travel and subsistence expenses in accordance with the provisions of G.S. 138-5 49 
or G.S. 138-6 or travel and subsistence expenses in accordance with the provisions of 50 
G.S. 120-3.1, as applicable. 51  General Assembly Of North Carolina 	Session 2025 
DRH10161-MGa-124  	Page 3 
(e) Administrative Support. – All administrative support and other services required by 1 
the advisory council shall be provided by the School of Medicine of the University of North 2 
Carolina at Chapel Hill.Department. 3 
(f) Upon the recommendation of the Dean of the School of Medicine of the University 4 
of North Carolina at Chapel Hill, Selection of Chair. – The Secretary shall select the chair of the 5 
advisory council from among the members of the council. The chair shall serve in this position 6 
until the expiration of his or her term. 7 
(g) The chair shall convene the first meeting of the advisory council no later than October 8 
1, 2015. Meetings and Quorum. – A majority of the council members shall constitute a quorum. 9 
A majority vote of a quorum shall be required for any official action of the advisory council. 10 
Following the first meeting, the advisory council shall meet at least quarterly. The advisory 11 
council may meet more frequently upon the call of the chair or upon the request of a majority of 12 
council members. 13 
"§ 130A-33.66.  Advisory Council on Rare Diseases; powers and duties; reports. 14 
The advisory council shall have the following powers and duties: 15 
(1) Advise on coordinating the Governor, the Secretary, and the General 16 
Assembly on all of the following: 17 
a. Coordination of statewide efforts for the to study of the incidence of 18 
rare diseases within the State and the status of the rare disease 19 
community. 20 
b. Coordination of statewide efforts to increase public awareness and 21 
understanding of rare diseases. 22 
c. Identification of policy issues related to rare diseases and the 23 
advancement of policy initiatives related to rare diseases at the State 24 
and federal levels. 25 
d. The appropriation of State funds to facilitate increased public 26 
awareness of and improved treatment for rare diseases. 27 
(2) Report to the Secretary, the Governor, and the Joint Legislative Oversight 28 
Committee on Health and Human Services Services, and the Fiscal Research 29 
Division on behalf of the General Assembly not later than January 1, 2016, 30 
and annually thereafter, on the activities of the advisory council and its 31 
findings and recommendations regarding rare disease research and care in 32 
North Carolina, including any recommendations for statutory changes and 33 
amendments to the structure, organization, and powers or duties of the 34 
advisory council. 35 
(3) In consultation with accredited medical schools, accredited schools of public 36 
health, and hospitals licensed to operate in the State that provide care to 37 
persons diagnosed with a rare disease, develop resources or recommendations 38 
regarding quality of and access to treatment and services available within the 39 
State for persons diagnosed with a rare disease. 40 
(4) Advise and consult with the Department, the North Carolina Drug Utilization 41 
Review Board, and the Medicaid Preferred Drug List Review Panel in 42 
developing recommendations, resources, and programs relating to the 43 
diagnosis and treatment of rare diseases. 44 
(5) Identify additional relevant areas for the advisory council to study and 45 
evaluate." 46 
SECTION 2. Effective July 1, 2025, there is appropriated from the General Fund to 47 
the Department of Health and Human Services the sum of two hundred fifty thousand dollars 48 
($250,000) in recurring funds for the 2025-2026 fiscal year and the sum of two hundred fifty 49 
thousand dollars ($250,000) in recurring funds for the 2026-2027 fiscal year to be allocated to 50  General Assembly Of North Carolina 	Session 2025 
Page 4  	DRH10161-MGa-124 
cover the operating expenses of the Advisory Council on Rare Diseases authorized by Section 1 1 
of this act. 2 
SECTION 3. Except as otherwise provided, this act is effective when it becomes 3 
law. 4